Altimmune is a late-stage biopharmaceutical company developing novel therapies for serious liver diseases, with its primary asset being pemvidutide, a balanced glucagon/GLP-1 dual receptor agonist candidate in clinical development for metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcoholic liver disease. The company operates through research and development activities funded by equity and debt financing, with no product revenue to date and reliance on clinical trials, manufacturing of trial materials, and regulatory work to advance its pipeline. Altimmune targets orphan and specialty indications in the liver disease space where significant unmet medical needs exist, and funds operations through a combination of term debt, equity financing, and at-the-market offerings.